EGFR and non-small cell lung carcinoma: In a retrospective study involving 145 patients, Xu et al. reported that consolidative LAT to brain metastasis improved the median OS for patients with oligometastatic stage IV EGFRm NSCLC without progression after initial EGFR TKI (38.2 vs. 29.2 months, HR = 0.48, p = 0.002).